The 2026 Specialty Drug Surge Part 2: How Employers Are Rewriting Their Pharmacy Strategies
Specialty drugs have been a major cost driver for years, but 2026 marks a turning point in both scale and urgency. With GLP 1 medications expanding into new indications, gene therapies entering the market at record pace, and oncology drugs continuing to rise in both cost and utilization, specialty medications are projected to account for more than 60% of total pharmacy spending this year. Employers of all sizes are confronting a new reality: traditional pharmacy strategies are no longer enough to manage the financial and operational impact of these high cost therapies.
Across national employer surveys and early 2026 claims data, a consistent picture is emerging. Employers are shifting from incremental adjustments to full scale redesigns of their pharmacy programs. The focus is no longer just on cost containment—it is on sustainability, access, and long term risk management.
1. GLP 1 Expansion Is Reshaping Pharmacy Budgets
GLP 1 medications such as Ozempic, Wegovy, and Zepbound continue to dominate pharmacy conversations, but the story in 2026 is broader than weight loss. New approvals for cardiovascular risk reduction, metabolic disease management, and combination therapies are driving utilization far beyond initial projections.
Employers are responding by:
- Implementing step therapy and clinical criteria
- Exploring outcomes based contracts with PBMs and manufacturers
- Offering lifestyle and coaching programs alongside medication
Surveys show that employers remain committed to covering GLP 1s, but they are increasingly focused on ensuring appropriate use and measurable outcomes.
2. Gene Therapies Are Creating New Financial Pressures
The FDA approved more gene therapies in 2025 than in any previous year, and 2026 is on track to exceed that record. These treatments—often priced in the millions—offer life changing benefits but create significant financial volatility for employer plans.
Employers are responding by:
- Purchasing stop loss coverage specifically for gene therapy claims
- Considering carve outs to specialized vendors
- Evaluating “pay over time” financing models
The challenge is balancing access to breakthrough treatments with the need to protect plan solvency.
3. Oncology Drugs Continue to Drive High Cost Utilization
Cancer remains one of the most expensive and complex areas of specialty pharmacy. New targeted therapies and immunotherapies are improving outcomes but increasing costs. Employers are seeing rising utilization not only in treatment but also in diagnostics and companion testing.
Employers are responding by:
- Partnering with oncology centers of excellence
- Using case management to coordinate care
- Reviewing coverage for high cost diagnostics
Oncology spend is expected to grow steadily through 2026, making it a top priority for long term planning.
4. Employers Are Reassessing PBM Relationships
The specialty drug surge is accelerating a broader shift in how employers evaluate their PBM contracts. Transparency, pass through pricing, and specialty drug management programs are now central to vendor selection.
Employers are responding by:
- Renegotiating rebate structures
- Demanding clearer reporting on specialty utilization
- Exploring alternative PBM models
Many employers are also turning to independent consultants to audit PBM performance and identify hidden costs.
5. New Plan Designs Are Emerging to Balance Access and Affordability
To manage rising specialty costs without reducing coverage, employers are adopting innovative plan designs that emphasize value, navigation, and clinical oversight.
Common strategies include:
- Prior authorization tied to evidence based guidelines
- Specialty pharmacy networks with negotiated pricing
- Integrated care models combining pharmacy and medical management
These approaches aim to ensure that employees receive the right medication at the right time—while keeping plans financially sustainable.
Across the benefits landscape, the message is clear: specialty drugs are no longer a niche concern. They are the defining cost and strategy challenge of 2026. Employers who take a proactive, data driven approach—especially in GLP 1 management, gene therapy financing, oncology coordination, and PBM oversight—will be best positioned to maintain both affordability and access in the year ahead.
This Just In ... Telehealth 2.0 Gains Momentum as Virtual Specialty Care Expands in 2026
The 2026 Specialty Drug Surge Part 2: How Employers Are Rewriting Their Pharmacy Strategies
Mental Health Parity Enforcement Part 2: A New Compliance Reality for Employers
Financial Wellness and Household Stability: Why Employers Are Making It a 2026 Priority
Rising Healthcare Costs and Affordability Pressures
The information presented and conclusions within are based upon our best judgment and analysis. It is not guaranteed information and does not necessarily reflect all available data. Web addresses are current at time of publication but subject to change. SmartsPro Marketing and The Insurance 411 do not engage in the solicitation, sale or management of securities or investments, nor does it make any recommendations on securities or investments. This material may not be quoted or reproduced in any form without publisher's permission. All rights reserved. ©2026 Smarts Publishing https://smartspublishing.com/ Tel. 877-762-7877.